Cue Biopharma, Inc. (CUE) Tops Q2 EPS by 8c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Piper Sandler Reiterates Overweight Rating on Cue Biopharma (CUE)
August 20, 2024 5:16 AM EDTPiper Sandler analyst Ed Tenthoff reiterated an Overweight rating and $3.00 price target on Cue Biopharma (NASDAQ: CUE).
The analyst comments "Cue and partner Ono anticipate selecting a development candidate for CUE-401 for autoimmune and inflammatory diseases in 1H:25, on which... More
